Edgewise Therapeutics announced submission of the STRATUS-HCM Phase 3 protocol for EDG-7500, a drug for symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The trial design includes two independent placebo-controlled studies under one protocol, with dose escalation based on investigator assessment rather than echocardiograms, reducing patient monitoring burden. The primary endpoint is peak oxygen consumption over 24 weeks, with about 600 patients expected to enroll. The trial is on track to start in the fourth quarter of 2026, aiming to offer a more accessible treatment for HCM patients.
Edgewise Therapeutics (EWTX) shares rose 6.58% to USD 40.00 on Pluang as of Nov 05, 2026 20:13 WIB, reflecting strong investor interest following the announcement of their Phase 3 protocol submission for EDG-7500 in hypertrophic cardiomyopathy. The stock’s market cap stands at $4.08 billion, with a 52-week trading range from $17.09 to $48.35. This momentum highlights growing attention to the company’s development pipeline in the health sector.
